Abstract
Background: The 21-gene Recurrence Score® (RS) assay predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence. Thus, this test might be useful to guide adjuvant treatment decisions in HR+/HER2− early breast cancer (EBC). The Oncotype DXÒ Test clinical utility was validated worldwide in major trials including more than 63,000 patients. There are only few studies that investigate the correlation of Ki67 with tumor grade and RS result. The REMAR-Study was designed to assess this correlation as a prospective, non-interventional, multicenter and non-randomized study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
